Categories

Business Ideas
Business Opportunities
Corporate
Home Business
International Business
Management
Online Business
Public Company
Public Relations
Small Business

Popular Articles

Step on the gas
The need of the hour is to create meritorious uses of natural gas, such as by building new capacities.

Govt banks struggle, but private banks'credit growth picks up
After losing customer accounts to public sector banks at the height of the downturn, private sector banks seem to be on their way back.

News of the day

Markets spurt on positive global cues; auto, pharma, metals lead
The markets staged a spectacular rally on the back of positive overseas cues. The Sensex regained the psychological 17k mark to end at 17,198, stronger by 272 points, and the Nifty closed at 5,122, higher by 89 points. Auto, pharma, metal and high-beta realty stocks were the flavour of the day.
Online Business

Suven Life presents Alzheimer's drug data in Austria meet

Suven Life Sciences Limited, a Hyderabad-based biopharmaceutical company specialising in central nervous system (CNS) diseases, has presented the clinical Phase-I data for its SUVN-502 drug at the 2009 Alzheimer’s Association International Conference in Vienna, Austria. - Sanofi Pasteur buys majority stake in Shantha Bio - Granules Q1 net up 129% at Rs 6 cr - Govt hints nexus between private, state-owned vaccine units - Fakes make up 20-25% of Rs 85,000 cr pharma sales - Dr Reddy"s Q1 net zooms 120% at Rs 244 cr - Ranbaxy gets nod to sell Ran-Simvastatin tablets in Canada The study was conducted at Basel, Switzerland, under a clinical trial application approved by SwissMedic, the regulatory authority of Switzerland for therapeutic products. “The Phase-I clinical data has attracted a lot of scientific and commercial interest from global pharma companies. We believe that SUVN-502 has great potential to become a novel treatment for disorders affecting memory and cognition in Alzheimer’s, schizophrenia and other dementia,” Venkat Jasi, chief executive of Suven Life, said in a release on Monday. The necessary additional tox studies are already in progress to start the Phase-II proof-of-concept study during 2010. The company targets to launch SUVN-502 in the latter part of 2013 or early 2014. Other molecules in the same category under development include GlaxoSmithKline’s molecule, which is at present in Phase-II, said Ramakrishna Nirogi, vice-president (discovery research), Suven Life. Suven Life Sciences’ scrip is currently trading at Rs 22.10 on the BSE, up 6.76 per cent as against the previous close of Rs 20.70.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009